Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 5, 2009, Pages

  Zaba, Lisa C ^a   Suárez Fariñas, Mayte ^a   Fuentes Duculan, Judilyn ^a   Nograles, Kristine E ^a   Guttman Yassky, Emma ^a   Cardinale, Irma ^a   Lowes, Michelle A ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

etanercept; gene; psoriasis; TNF

Indexed keywords

CD1C ANTIGEN; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 8; LANGERIN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BONE MARROW CELL; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PSORIASIS VULGARIS; SEPSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DENDRITIC CELLS; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-8; MYELOID CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SKIN; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 71749085498     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.08.046     Document Type: Article

References (35)

1. Green S., Dobrjansky A., Carswell E.A., Kassel R.L., Old L.J., Fiore N., et al. Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 73 (1976) 381-385
2. Hoffman M.K. The effects of tumor necrosis factor on the production of interleukin-1 by macrophages. Lymphokine Res 5 (1986) 255-260
3. Clark I.A., Virelizier J.L., Carswell E.A., and Wood P.R. Possible importance of macrophage-derived mediators in acute malaria. Infect Immun 32 (1981) 1058-1066
4. Nickoloff B.J., and Stevens S.R. What have we learned in dermatology from the biologic therapies?. J Am Acad Dermatol 54 (2006) S143-S151
5. van Meurs J.B., van Lent P.L., van de Loo A.A., Holthuysen A.E., Bayne E.K., Singer II, et al. Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis. Ann Rheum Dis 58 (1999) 350-356
6. Koczan D., Drynda S., Hecker M., Drynda A., Guthke R., Kekow J., et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 10 (2008) R50
7. Gottlieb A.B. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther 17 (2004) 401-408
8. D'Haens G., and Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 8 (2006) 506-512
9. Diluvio L., Vollmer S., Besgen P., Ellwart J.W., Chimenti S., and Prinz J.C. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 176 (2006) 7104-7111
10. Chang J.C., Smith L.R., Froning K.J., Kurland H.H., Schwabe B.J., Blumeyer K.K., et al. Persistence of T-cell clones in psoriatic lesions. Arch Dermatol 133 (1997) 703-708
11. Prinz J.C., Grob B., Vollmer S., Trommler P., Strobel I., Meurer M., et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 24 (1994) 593-598
12. Weinshenker B.G., Bass B.H., Ebers G.C., and Rice G.P. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol 20 (1989) 1132-1133
13. Gottlieb S.L., Gilleaudeau P., Johnson R., Estes L., Woodworth T.G., Gottlieb A.B., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1 (1995) 442-447
14. Nestle F.O., and Nickoloff B.J. From classical mouse models of psoriasis to a spontaneous xenograft model featuring use of AGR mice. Ernst Schering Res Found Workshop 50 (2005) 203-212
15. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
16. Gottlieb A.B., Cooper K.D., McCormick T.S., Toichi E., Everitt D.E., Frederick B., et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 23 (2007) 1081-1092
17. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
18. Toichi E., Torres G., McCormick T.S., Chang T., Mascelli M.A., Kauffman C.L., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 177 (2006) 4917-4926
19. McKenzie B.S., Kastelein R.A., and Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27 (2006) 17-23
20. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez Farinas M., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204 (2007) 3183-3194
21. Haider A.S., Lowes M.A., Suarez-Farinas M., Zaba L.C., Cardinale I., Khatcherian A., et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 180 (2008) 1913-1920
22. Nograles K., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez Farinas M., Cardinale I., et al. Th17 cytokines IL-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159 (2008) 1092-1102
23. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005) 15545-15550
24. Commins S., Steinke J.W., and Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 121 (2008) 1108-1111
25. Su A.I., Wiltshire T., Batalov S., Lapp H., Ching K.A., Block D., et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101 (2004) 6062-6067
26. Kasperska-Zajac A., and Rogala B. Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome. Inflammation 29 (2005) 90-93
27. Zaba L.C., Fuentes-Duculan J., Steinman R.M., Krueger J.G., and Lowes M.A. Normal human dermis contains distinct populations of CD11c + BDCA-1+ dendritic cells and CD163 + FXIIIA+ macrophages. J Clin Invest 117 (2007) 2517-2525
28. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129 (2009) 79-88
29. Yamazaki T., Yang X.O., Chung Y., Fukunaga A., Nurieva R., Pappu B., et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181 (2008) 8391-8401
30. Krueger G., and Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 140 (2004) 218-225
31. Nair R.P., Ruether A., Stuart P.E., Jenisch S., Tejasvi T., Hiremagalore R., et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 128 (2008) 1653-1661
32. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008) 1675-1684
33. Chomarat P., Dantin C., Bennett L., Banchereau J., and Palucka A.K. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 171 (2003) 2262-2269
34. Basso A.S., Cheroutre H., and Mucida D. More stories on Th17 cells. Cell Res 19 (2009) 399-411
35. Ortega C., Fernandez A.S., Carrillo J.M., Romero P., Molina I.J., Moreno J.C., et al. IL-17-producing CD8 + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol (2009)